REQUEST A DEMO
Total
USD $0.00
Search more companies

Grannus Pharma Sp. z o.o. (Poland)

Main Activities: Pharmaceutical Preparation Manufacturing
Full name: Grannus Pharma Sp. z o.o. Profile Updated: June 02, 2021
Buy our report for this company USD 19.99 Most recent financial data: 2019 Available in: English & Polish Download a sample report

Grannus Pharma Sp. z o.o. is based in Poland, with the head office in Warsaw. The company operates in the Pharmaceutical Preparation Manufacturing sector. The enterprise was incorporated on May 22, 2014. 5 (2014) employees currently work for Grannus Pharma Sp. z o.o.. Its’ total assets recorded a negative growth of 9.31%.

Headquarters
Ul. Topolowa 24 A
Warsaw; Mazowieckie; Postal Code: 03-138

Contact Details: Purchase the Grannus Pharma Sp. z o.o. report to view the information.

Basic Information
Total Employees:
Purchase the Grannus Pharma Sp. z o.o. report to view the information.
Outstanding Shares:
Purchase the Grannus Pharma Sp. z o.o. report to view the information.
Registered Capital:
Purchase the Grannus Pharma Sp. z o.o. report to view the information.
Incorporation Date:
May 22, 2014
Key Executives
Purchase this report to view the information.
President
Ownership Details
Purchase this report to view the information.
100%
Company Performance
Financial values in the chart are available after Grannus Pharma Sp. z o.o. report is purchased.
Looking for more than just a company report?

EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.

Request a demo of the EMIS service
Key Financial Highlights
Annual growth percentages for latest two years in local currency PLN. Absolute financial data is included in the purchased report.
Operating profit (EBIT)
-23.72%
Net Profit (Loss) for the Period
21.49%
Total assets
-9.31%
Total equity
-9.31%
Return on Equity (ROE)
1.59%

To view more information, Request a demonstration of the EMIS service

Buy this company report
Need ongoing access to company, industry or country information?